<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian Dermatol Online J</journal-id><journal-id journal-id-type="iso-abbrev">Indian Dermatol Online J</journal-id><journal-id journal-id-type="publisher-id">IDOJ</journal-id><journal-title-group><journal-title>Indian Dermatology Online Journal</journal-title></journal-title-group><issn pub-type="ppub">2229-5178</issn><issn pub-type="epub">2249-5673</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27559523</article-id><article-id pub-id-type="pmc">4976428</article-id><article-id pub-id-type="publisher-id">IDOJ-7-335</article-id><article-id pub-id-type="doi">10.4103/2229-5178.185471</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letters to the Editor</subject></subj-group></article-categories><title-group><article-title>Comparative assessment of the efficacy of topical ketoconazole and topical luliconazole in cases of pityriasis versicolor at a tertiary care hospital in eastern India: A prospective, open, randomized controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sarkar</surname><given-names>Somenath</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Sengupta</surname><given-names>Dipayan</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Basak</surname><given-names>Sukumar</given-names></name><xref ref-type="aff" rid="aff2">1</xref></contrib><contrib contrib-type="author"><name><surname>Damji</surname><given-names>Shabab Ahmed</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Shukla</surname><given-names>Devesh Kumar</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Anurag</surname><given-names>Deep</given-names></name><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff id="aff1">Department of Dermatology, Venereology and Leprosy, School of Tropical Medicine, Kolkata, India</aff><aff id="aff2"><label>1</label>Department of Microbiology, Burdwan Medical College, Burdwan, West Bengal, India</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Dipayan Sengupta, Department of Dermatology, Venereology and Leprosy, School of Tropical Medicine, 108 CR Avenue, Kolkata - 700 073, West Bengal, India. E-mail: <email xlink:href="undefined.santaaaaa@gmail.com">undefined.santaaaaa@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Jul-Aug</season><year>2016</year></pub-date><volume>7</volume><issue>4</issue><fpage>335</fpage><lpage>336</lpage><permissions><copyright-statement>Copyright: &#x000a9; Indian Dermatology Online Journal</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.</license-p></license></permissions></article-meta></front><body><p>Sir,</p><p>Pityriasis versicolor, also known as tinea versicolor is a superficial chronically recurring fungal infection of the stratum corneum, characterized by scaly, dyspigmented irregular macules most often occurring on the trunk and extremities.[<xref rid="ref1" ref-type="bibr">1</xref>] The organism can easily be diagnosed by treating skin scraping with 10% KOH,[<xref rid="ref2" ref-type="bibr">2</xref>] and shows short, thick hyphae with a large number of variously sized spores (spaghetti and meat-ball appearance). Many systemic and topical antifungals in various forms are used in the treatment of pityriasis versicolor with an overall positive result.</p><p>Our study was carried out over three months among 86 consecutive patients of pityriasis versicolor attending the dermatology outpatient department. A thorough clinical examination was done to determine the characteristics and distribution of lesions, and any other associated dermatological or systemic diseases. Skin scrapings were collected from the active (symptomatic) lesion and treated with 10% KOH. Mycological confirmation was done under the microscope. After informed consent, patients were randomly allocated to two groups by coin flipping method. The first group was advised to apply ketoconazole 2% cream twice daily and second group were asked to apply topical luliconazole 1% cream twice daily. On the 14<sup>th</sup> and 28<sup>th</sup> day, the therapeutic response was evaluated and KOH preparation of skin scrapings was repeated. There were a total six dropouts (two in first follow-up and four in the second follow-up), whose data was excluded during the final calculation.</p><p>Among the 80 patients with pityriasis versicolor, 55 (68.75%) patients were male and 25 (31.25%) patients were female, with a male preponderance (M: F = 2.2:1). Forty-two patients (52.5%) were in the age group of 21&#x02013;40 years. The disease was rare above 60 years of age (4.55%). At baseline, KOH mount was positive in 80% case in the ketoconazole group and 85% in the luliconazole group. At first follow up (day 14), KOH mount negativity among the ketoconazole group was 67.50% and in the luliconazole group it was 80.00%. At the second follow up (day 28), KOH mount was negative in 72.50% in the ketoconazole group and 92.50% in the luliconazole group.</p><p>Individual improvement within both groups was statistically significant at the follow ups (<italic>P</italic> &#x0003c; 0.0001). Comparison between two groups showed that there was no statistically significant difference between two groups at first follow up (<italic>P</italic> = 0.2178). However, at the second follow up the improvement in luliconazole-treated group was better than in the ketoconazole-treated group (<italic>P</italic> = 0.0367), which is statistically significant [<xref ref-type="table" rid="T1">Table 1</xref> and <xref ref-type="fig" rid="F1">Figure 1</xref>].</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Number of patients with negative KOH mount in each group, at baseline, after 14 days and after 28 days</p></caption><graphic xlink:href="IDOJ-7-335-g001"/></table-wrap><fig id="F1" position="float"><label>Figure 1</label><caption><p>Graphical representation of KOH mount negativity in each group, as they increases over time</p></caption><graphic xlink:href="IDOJ-7-335-g002"/></fig><p>Different modalities of treatment are available for pityriasis versicolor including topical and systemic azoles, allylamines and also selenium sulphide. However, a recent evidence based review concluded most treatment options were similarly effective in the treatment of pityriasis versicolor but randomized controlled trials are needed to compare their relative efficacies.[<xref rid="ref3" ref-type="bibr">3</xref>]</p><p>Ketoconazole is a water-soluble imidazole derivative. It is a synthetic antimycotic with a broad spectrum of activity against dermatophytes and yeasts.[<xref rid="ref4" ref-type="bibr">4</xref><xref rid="ref5" ref-type="bibr">5</xref>] Ketoconazole exhibits a wide spectrum of activity against dermatophytes, <italic>Candida</italic>, <italic>Malassezia in vitro</italic>.[<xref rid="ref6" ref-type="bibr">6</xref>] In this study we have used 2% ketoconazole cream, which has previously shown 80%&#x02013;90% cure rate in the treatment of pityriasis versicolor.[<xref rid="ref7" ref-type="bibr">7</xref><xref rid="ref8" ref-type="bibr">8</xref><xref rid="ref9" ref-type="bibr">9</xref><xref rid="ref10" ref-type="bibr">10</xref>]</p><p>Luliconazole is a novel, optically active imidazole antifungal.[<xref rid="ref11" ref-type="bibr">11</xref>] The compound has a unique chemical structure, which is augmented by introduction of a ketene dithioacetate structure in the imidazole moiety. It has high potency inhibitory action against filamentous fungi, including dermatophytes. Preliminary studies suggested that luliconazole could also be effective against <italic>Malassezia</italic> species.[<xref rid="ref12" ref-type="bibr">12</xref>]</p><p>In this study we have found both luliconazole and ketoconazole to be effective in the treatment of pityriasis versicolor. However, over a 4-week period, luliconazole was found to be more effective than ketoconazole.</p><sec disp-level="2" id="sec2-1"><title>Financial support and sponsorship</title><p>Nil.</p></sec><sec disp-level="2" id="sec2-2"><title>Conflicts of interest</title><p>There are no conflicts of interest.</p></sec></body><back><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hay</surname><given-names>RJ</given-names></name><name><surname>Ashbee</surname><given-names>HR</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Burns</surname><given-names>T</given-names></name><name><surname>Breathnach</surname><given-names>S</given-names></name><name><surname>Cox</surname><given-names>N</given-names></name><name><surname>Griffiths</surname><given-names>C</given-names></name></person-group><article-title>Mycology</article-title><source>Rook's Textbook of Dermatology</source><year>2010</year><edition>8th ed</edition><publisher-name>Wiley-Blackwell</publisher-name><fpage>36.1</fpage><lpage>36.93</lpage></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>AK</given-names></name><name><surname>Batra</surname><given-names>R</given-names></name><name><surname>Bluhm</surname><given-names>R</given-names></name><name><surname>Faergemann</surname><given-names>J</given-names></name></person-group><article-title>Pityriasis versicolor</article-title><source>Dermatol Clin</source><year>2003</year><volume>21</volume><fpage>413</fpage><pub-id pub-id-type="pmid">12956196</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>SW</given-names></name><name><surname>Bigby</surname><given-names>M</given-names></name></person-group><article-title>Pityriasis versicolor: A systematic review of interventions</article-title><source>Arch Dermatol</source><year>2010</year><volume>146</volume><fpage>1132</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">20956647</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Odds</surname><given-names>FC</given-names></name><name><surname>Milne</surname><given-names>LJ</given-names></name><name><surname>Gentles</surname><given-names>JC</given-names></name><name><surname>Ball</surname><given-names>EH</given-names></name></person-group><article-title>The activity <italic>in vitro</italic> and <italic>in vivo</italic> of a new imidazole antifungal Ketoconazole</article-title><source>J Antimicrobe Chemother</source><year>1980</year><volume>6</volume><fpage>97</fpage><lpage>104</lpage></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thienpont</surname><given-names>D</given-names></name><name><surname>Van Cutsem</surname><given-names>J</given-names></name><name><surname>Van Gerven</surname><given-names>F</given-names></name><name><surname>Heeres</surname><given-names>J</given-names></name><name><surname>Janssen</surname><given-names>PA</given-names></name></person-group><article-title>Ketoconazole - a new broad spectrum orally active antimycotic</article-title><source>Experientia</source><year>1979</year><volume>35</volume><fpage>606</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">446651</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heeres</surname><given-names>J</given-names></name><name><surname>Backx</surname><given-names>LJ</given-names></name><name><surname>Mostmans</surname><given-names>JH</given-names></name><name><surname>Van Cutsem</surname><given-names>J</given-names></name></person-group><article-title>Antimycotic imidazoles. Part 4. Synthesis and antifungal activity of ketoconazole, a new potent orally active broad-spectrum antifungal agent</article-title><source>J Med Chem</source><year>1979</year><volume>22</volume><fpage>1003</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">490531</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savin</surname><given-names>RC</given-names></name><name><surname>Horwitz</surname><given-names>SN</given-names></name></person-group><article-title>Double-blind comparison of 2% ketoconazole cream and placebo in the treatment of pityriasis versicolor</article-title><source>J Am Acad Dermatol</source><year>1986</year><volume>15</volume><fpage>500</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">3760275</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balwada</surname><given-names>RP</given-names></name><name><surname>Jain</surname><given-names>VK</given-names></name><name><surname>Dayal</surname><given-names>S</given-names></name></person-group><article-title>A doubleblind comparison of 2% ketoconazole and 1% clotrimazole in the treatment of pityriasis versicolor</article-title><source>Indian J Dermatol Venereol Leprol</source><year>1996</year><volume>62</volume><fpage>298</fpage><lpage>300</lpage><pub-id pub-id-type="pmid">20948094</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chopra</surname><given-names>V</given-names></name><name><surname>Jain</surname><given-names>VK</given-names></name></person-group><article-title>Comparative study of topical terbinafine and topical ketoconazole in pityriasis versicolor</article-title><source>Indian J Dermatol Venereol Leprol</source><year>2000</year><volume>66</volume><fpage>299</fpage><lpage>300</lpage><pub-id pub-id-type="pmid">20877107</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagpal</surname><given-names>VB</given-names></name><name><surname>Jain</surname><given-names>VK</given-names></name><name><surname>Aggarwal</surname><given-names>K</given-names></name></person-group><article-title>Comparative study of oral and topical ketoconazole therapy in pityriasis versicolor</article-title><source>Indian J Dermatol Venereol Leprol</source><year>2003</year><volume>69</volume><fpage>287</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">17642914</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niwano</surname><given-names>Y</given-names></name><name><surname>Kuzuhara</surname><given-names>N</given-names></name><name><surname>Kodama</surname><given-names>H</given-names></name><name><surname>Yoshida</surname><given-names>M</given-names></name><name><surname>Miyazaki</surname><given-names>T</given-names></name><name><surname>Yamaguchi</surname><given-names>H</given-names></name></person-group><article-title><italic>In vitro</italic> and <italic>in vivo</italic> antidermatophyte activities of NND-502, a novel optically active imidazole antimycotic agent</article-title><source>Antimicrob Agents Chemother</source><year>1998</year><volume>42</volume><fpage>967</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">9559824</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uchida</surname><given-names>K</given-names></name><name><surname>Nishiyama</surname><given-names>Y</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Yamaguchi</surname><given-names>H</given-names></name></person-group><article-title><italic>In vitro</italic> activity of novel imidazole antifungal agent NND-502 against <italic>Malassezia</italic> species</article-title><source>Int J Antimicrob Agents</source><year>2003</year><volume>21</volume><fpage>234</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">12636984</pub-id></element-citation></ref></ref-list></back></article>